Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282064 | 0.76 | CES2 (0.43) | CES2CES1ACLYCA2ALDH1A1 | |
| SCHEMBL1416183 | 0.76 | CES2 (0.38) | CES2CES1ACLYCA2ALDH1A1 | |
| SCHEMBL12674291 | 0.76 | CES2 (0.34) | CES2CES1ACLYCA2 | |
| SCHEMBL12666578 | 0.76 | L3MBTL1 (0.48) | CES2CES1ACLYCA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28195525 | 0.74 | CES2 (0.41) | CES2CES1ACLYCA2ALDH1A1 | |
| SCHEMBL5138444 | 0.74 | CES2 (0.41) | CES2CES1ACLYCA2ALDH1A1 | |
| SCHEMBL5215479 | 0.74 | ENPP2 (0.38) | CA2PTGS2 | |
| SCHEMBL5138441 | 0.74 | CES2 (0.37) | CES2CES1ACLYCA2ALDH1A1 | |
| SCHEMBL23569834 | 0.73 | CA2 (0.36) | CES2CES1ACLYCA2ALDH1A1 | |
| SCHEMBL15880882 | 0.71 | CA2 (0.39) | CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102164908-B | Selective estrogen repector modulator for the treatment of osteoarthritis | LILLY CO ELI | 2013-08-28 | — | — | CN | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| CN-102164908-A | Selective estrogen repector modulator for the treatment of osteoarthritis | LILLY CO ELI | 2011-08-24 | — | — | CN | disclosed |
| EP-2342189-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF OSTEOARTHRITIS | ELI LILLY AND COMPANY (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010036497-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036497-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2009070873-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD. (CA) | 2009-06-11 | — | — | WO | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-0100172-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-08-12 | — | — | EP | disclosed |
| US-4636505-A | ANTIANDROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-01-13 | — | — | US | disclosed |
| EP-0100172-A1 | Amide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | GPR119, GPR52, GPR35 | CES2 1967/4885CES1 890/4885ACLY 1821/4885 |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ESRRA, GPER1, ESR2 | CES2 4260/4885CES1 1497/4885ACLY 2705/4885 |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | CES2 261/4885CES1 542/4885ACLY 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.